UBA5-Related Developmental and Epileptic Encephalopathy: Comprehensive Research Report

1. Disease Information

Overview

UBA5-related developmental and epileptic encephalopathy — formally Developmental and Epileptic Encephalopathy 44 (DEE44), and historically termed "Early Infantile Epileptic Encephalopathy-44 (EIEE44)" — is an ultra-rare, autosomal recessive neurodevelopmental disorder caused by biallelic (homozygous or compound heterozygous) loss-of-function variants in UBA5, which encodes the E1-like activating enzyme of the UFMylation post-translational modification pathway. The disorder was first described in 2016 in three back-to-back reports (Colin et al., Duan et al., Muona et al., all Am J Hum Genet 99(3)), making UBA5 "the first gene from the ufmylation pathway... linked to disease" (PMC8208045). It is characterized by early-onset (typically first weeks to months of life) refractory epilepsy/infantile spasms, severe global developmental delay/intellectual disability, hypotonia with limb hypertonia, dystonia, microcephaly, failure to thrive, and progressive white-matter/cerebellar abnormalities on MRI (OMIM #617132; eLife 89891).

Biallelic UBA5 variants produce a phenotypic spectrum along a severity continuum rather than a single discrete disease, spanning three overlapping presentations: 1. DEE44 — severe infantile-onset encephalopathy with/without seizures (the majority phenotype) 2. Autosomal recessive spinocerebellar ataxia 24 (SCAR24, OMIM #617133) — milder, childhood-onset progressive gait/limb ataxia with normal-to-preserved cognition 3. Severe congenital neuropathy — profound sensorimotor peripheral neuropathy, sometimes fatal in infancy, with or without CNS involvement

(Genomics England PanelApp; PMC10691876)

Key Identifiers

• OMIM disease: #617132 (DEE44); related #617133 (SCAR24)
• OMIM gene: *610552 (UBA5)
• Gene: UBA5 — HGNC:23230, chromosome 3q22.1
• UniProt: Q9GZZ9
• Inheritance: Autosomal recessive
• Synonyms: Early infantile epileptic encephalopathy 44 (EIEE44, older nomenclature); UBA5-related encephalopathy; UBA5-associated encephalopathy; UBA5 deficiency

Data Source Type

Nearly all clinical knowledge derives from aggregated case reports and small case series (individual patients and sibships) rather than large EHR-based cohorts, reflecting the extreme rarity of the condition — as of the most comprehensive published review, 24 individuals from ~17–19 families had been reported (PMC8208045; eLife 89891, reporting "21/25" analyzed individuals).

2. Etiology

Disease Causal Factor

Purely monogenic/genetic: biallelic pathogenic variants in UBA5 causing partial-to-severe loss of UFM1-activating (E1) enzymatic function. There is no known environmental, infectious, or purely acquired cause.

Genetic Risk Factors

• Compound heterozygosity is the dominant genotype: most reported patients carry one severe/null allele in trans with a hypomorphic (partial-function) allele — a pattern essential to viability, since complete biallelic null UBA5 is likely embryonic/perinatally lethal (consistent with murine data below).
• Recurrent hypomorphic allele p.Ala371Thr (c.1111G>A): found in ~65–70% of DEE44 alleles reported (12/17 families in one series), functioning as a weak/mild hypomorphic variant that preserves partial E1 activity. Population database carrier frequencies are estimated at 1 in 84 in Finnish populations and 1 in 200 in non-Finnish Europeans, and homozygosity for p.A371T alone is reported in asymptomatic adults in population databases — establishing it as a "very weak allele" below a pathogenic threshold on its own (PMC8208045; eLife 89891).
• Founder homozygous variant p.Arg11Trp (c.31C>T) identified in a consanguineous multigenerational family, associated with a fatal congenital neuropathy phenotype (ResearchGate/J Med Genet).
• No modifier genes have yet been formally established, though allelic strength (see §4) is itself the principal determinant of phenotype severity.

Risk Factors

• Consanguinity increases risk of biallelic pathogenic combinations, particularly for the severe congenital-neuropathy phenotype.
• No age, sex, lifestyle, or occupational risk factors are known (Mendelian recessive disease).

Protective Factors

• Genetically, inheriting two mild/hypomorphic alleles (e.g., homozygous p.A371T) appears protective/asymptomatic — a genotype–phenotype threshold effect rather than a distinct "protective variant."
• No environmental or lifestyle protective factors identified.

Gene-Environment Interactions

None established; this is considered a purely monogenic disorder with no reported environmental modifiers of penetrance or expressivity.

3. Phenotypes

Core Clinical Features (with suggested HPO terms)

Phenotype Characteristics

• Onset: Most cases present in early infancy — "refractory infantile spasms or myoclonus usually in the first weeks or months of life, up to about 12 months of age" (OMIM). The most severe reported genotype caused burst-suppression encephalopathy within hours of birth, with death at 16 days. Conversely, seizure onset was delayed to childhood in some patients, and the milder SCAR24 phenotype presents with ataxia onset at 5–8 years of age.
• Severity: Highly variable, ranging from neonatal-lethal encephalopathy to milder ataxia-predominant disease with preserved cognition in adulthood — directly correlating with residual UFM1-activating enzymatic activity (allelic strength; see §4/§6).
• Progression: Generally progressive for both the encephalopathy (worsening motor/cognitive trajectory, evolving MRI abnormalities — "imaging was normal in the first months of life but later showed abnormalities" in many patients) and the SCAR24 ataxia phenotype (one adult sibling lost ambulation by age 39).
• Frequency among affected individuals: See table above; based on small aggregated cohorts (n≈24–25), so percentages should be interpreted cautiously.

Quality of Life Impact

Severely affected individuals experience profound lifelong disability: non-ambulation, minimal-to-absent verbal communication, inability to hold the head upright, and dependence on caregivers for all activities of daily living. Refractory dystonia/status dystonicus can be life-threatening and has required emergency deep brain stimulation (PMID:37130202). Failure to thrive despite adequate nutrition adds additional medical burden; the pituitary gland is notably the highest UBA5-expressing tissue in GTEx, raising a hypothesized but unconfirmed growth-hormone-axis contribution.

4. Genetic/Molecular Information

Causal Gene

• UBA5 (OMIM *610552), chromosome 3q22.1, encodes an E1-like ubiquitin-activating enzyme (EC 6.2.1.45) that is the sole known activator of UFM1 (ubiquitin-fold modifier 1).

Pathogenic Variants

• Gene: UBA5, HGNC:23230
• Variant classification: Missense (majority — affecting the adenylation/catalytic domain), nonsense (e.g., p.Arg188*), frameshift, and rare intronic/splice variants, all loss-of-function to varying degrees.
• Variant type/class and functional impact: Systematic biochemical and in vivo (humanized Drosophila) characterization of 13+ missense variants stratified them into four allelic-strength classes — Group IA/IB (mild hypomorphs; full or near-full lethality rescue in flies but progressive phenotypes), Group II (partial rescue; developmental delay, seizure-like behavior), and Group III (severe loss-of-function; failed rescue, insoluble/misfolded protein), plus Group IV null/frameshift alleles (eLife 89891). "There is a strong correlation between in vivo and in vitro phenotypes, establishing a classification of LoF variants into mild, intermediate, and severe allelic strengths."
• Key recurrent variants:
• p.Ala371Thr (c.1111G>A) — recurrent hypomorphic allele in ~65–70% of DEE44 alleles, always found in trans with a more severe variant in symptomatic individuals; homozygous in some asymptomatic adults; shows temperature-dependent loss of UFM1 transthiolation activity at 22°C but not 37°C in vitro.
• p.Tyr53Phe (c.158A>T) (homozygous) — associated with the most severe reported phenotype (death from status epilepticus); E1 activity reduced to 3.4% and E2 (transthiolation) activity to 6.8% of wild type.
• p.Arg11Trp (c.31C>T) (homozygous, founder in a consanguineous family) — fatal congenital neuropathy.
• p.Cys303Arg, p.Leu254Pro — novel variants causing significant functional impairment, each identified in two unrelated families/sibships.
• Catalytic residue: Cys250 forms the active-site thioester bond with UFM1's C-terminal glycine after ATP-dependent adenylation; the engineered enzyme-dead control p.Cys250Ala is used as a null reference in functional assays.
• Allele frequency: p.A371T carrier frequency ~1/84 (Finnish) and ~1/200 (non-Finnish European) in population databases (gnomAD-derived), consistent with a founder/recurrent hypomorphic allele rather than a fully deleterious one.
• Somatic vs. germline: Exclusively germline; no somatic mosaicism reported.
• Functional consequence: Loss of function (partial to near-complete) of UBA5's E1-activating enzymatic activity — reduced ATP binding, reduced UFM1 adenylation, reduced thioester (transthiolation) formation, and/or reduced protein stability/solubility, depending on variant location (buried structural residues → misfolding/insolubility; ATP-pocket residues → reduced catalysis without stability loss).

Modifier Genes

None formally established; allelic strength of the two UBA5 alleles themselves is the principal known modifier of phenotype.

Epigenetic Information

Not established for this disease specifically (UFMylation itself is increasingly recognized as intersecting broadly with chromatin/DNA-damage-response biology, but disease-specific epigenetic data are not reported).

Chromosomal Abnormalities

None reported; this is a single-gene point-mutation/small-indel disorder, not a copy-number or structural chromosomal condition.

5. Environmental Information

No environmental toxins, occupational exposures, lifestyle factors, or infectious triggers have been implicated in UBA5-DEE44 — it is a purely monogenic disease. No infectious agents are associated.

6. Mechanism / Pathophysiology

Molecular Pathway: UFMylation Cascade

UBA5 is the E1-activating enzyme of UFMylation, a ubiquitin-like post-translational modification (PTM) system parallel to but distinct from canonical ubiquitination. The cascade proceeds:

UBA5 (E1) → UFC1 (E2, UFM1-conjugating enzyme) → UFL1/UFBP1/CDK5RAP3 (E3 ligase complex) → substrate conjugation with UFM1

Mechanistically, UBA5 forms a homodimer that enables a trans-binding mechanism: UFM1 binds one subunit while the active site resides in the partner subunit. UBA5 first adenylates the C-terminal glycine of UFM1 (ATP-dependent), then forms a thioester bond via active-site Cys250, and finally transfers activated UFM1 to UFC1 (transthiolation) (BRENDA EC 6.2.1.45; PMC5428781).

Causal Chain (Trigger → Manifestation)

1. Biallelic UBA5 hypomorphic/null variants → reduced UBA5 protein stability, ATP binding, or catalytic (adenylation/thioester) activity
2. → Reduced global UFMylation flux (reduced UBA5–UFM1 and downstream substrate–UFM1 conjugates; zebrafish models show Ufm1-conjugates reduced to ~30% of wild type)
3. → Perturbed endoplasmic reticulum (ER) homeostasis and exacerbated unfolded protein response (UPR) — elevated phospho-PERK and phospho-eIF2α, increased nuclear ATF6 translocation and CHOP expression, decreased IRE1α stability and reduced spliced XBP1, ER expansion (calnexin staining), and increased PARP cleavage (apoptosis) in patient-derived organoid/cell models (Science Translational Medicine 2024/2025, PMID:38328212 preprint / PMID:40333994 published)
4. → Mitochondrial dysfunction: widespread mitochondrial pathology (abnormal cristae, vacuolated/"onion-ring" degenerating mitochondria, elevated full-length PINK1 indicating mitophagy activation) in zebrafish CNS, PNS, and skeletal muscle (Brain Communications 2023, PMC10691876)
5. → Neurodevelopmental disruption, most strikingly a severe GABAergic interneuron deficit in patient-derived cortical organoids (~15% GABAergic interneuron population vs. ~40% in controls, with reduced GAD1/GAD2/CALB2/SCGN expression) and microcephaly (patient organoids ~25% smaller than controls)
6. → Aberrant network electrophysiology: increased weighted mean firing rate and burst frequency, but paradoxically decreased network burst frequency, indicating impaired coordinated neuronal activity → clinical epileptogenesis and encephalopathy
7. → Downstream peripheral neurodegeneration (axonal/mitochondrial pathology in peripheral nerves) explains the neuropathy-predominant phenotypic pole, while cerebellar Purkinje/neuronal degeneration explains the ataxia-predominant pole (SCAR24)

Cell Types and Biological Processes Involved

• GABAergic interneurons (loss/reduced differentiation) — candidate CL term: CL:0000617 (GABAergic neuron)
• Cortical excitatory neurons (aberrant firing)
• Cerebellar neurons/Purkinje cells (degeneration in SCAR24-type phenotype and in zebrafish cerebellar pathology at 14 dpf)
• Peripheral sensorimotor neurons (axonal degeneration in neuropathy-predominant phenotype)
• Skeletal muscle (mitochondrial pathology in zebrafish)
• Suggested GO terms: GO:0071569 (protein UFmylation), GO:0006986 (response to unfolded protein / UPR), GO:0034976 (response to ER stress), GO:0007005 (mitochondrion organization), GO:0000422 (mitophagy)

Protein Dysfunction

Depending on variant location: loss of catalytic (adenylation/thioester) function at the active site, loss of ATP-binding capacity, or structural misfolding/insolubility for variants affecting buried hydrophobic residues (e.g., Gly168, Cys303) — demonstrated via thermal shift assays and purification studies in the eLife allelic-series paper.

Advanced/Omics Technologies Applied

• Patient-derived iPSC-cortical organoids with single-cell/marker-based transcriptomic characterization (GABAergic marker panel) and multi-electrode-array electrophysiology
• CRISPR-engineered isogenic cell lines (U-87 MG) modeling specific compound-heterozygous genotypes (UBA5^A371T/R55H, UBA5^A371T/F292*)
• CRISPRa (dCas9-VP64-p65-Rta) gene-activation and SINEUP synthetic lncRNA approaches to therapeutically upregulate UBA5 translation

7. Anatomical Structures Affected

• Organ level (primary): Central nervous system (brain — cortex, cerebellum, white matter, corpus callosum, thalami, hippocampus); in a subset of patients, the peripheral nervous system (peripheral nerves)
• Secondary/systemic: Growth failure/failure to thrive (possible pituitary/growth-hormone axis involvement, speculative); in SCAR24, eyes (cataracts) are also affected
• Body systems: Nervous system (primary); endocrine/growth axis (secondary, unconfirmed mechanism); musculoskeletal (secondary to hypertonia/dystonia)
• Tissue/cell level: Cerebral cortical neurons and GABAergic interneurons; cerebellar neurons; peripheral sensorimotor axons; skeletal muscle (mitochondrial pathology in models)
• Subcellular level: Endoplasmic reticulum (UPR activation, ER expansion), mitochondria (structural/functional pathology, mitophagy activation) — candidate GO Cellular Component terms: GO:0005783 (endoplasmic reticulum), GO:0005739 (mitochondrion)
• Localization (UBERON): UBERON:0000955 (brain), UBERON:0002037 (cerebellum), UBERON:0002336 (corpus callosum white matter), UBERON:0001017 (central nervous system), UBERON:0000010 (peripheral nervous system)
• Laterality: Bilateral/diffuse — not a lateralized process

8. Temporal Development

• Onset: Typically neonatal-to-early-infantile (first weeks to ~12 months) for DEE44; childhood (5–8 years) for the SCAR24 ataxia phenotype; congenital (in utero, reduced fetal movements) for the severe neuropathy phenotype.
• Onset pattern: Acute-to-subacute for the most severe neonatal encephalopathy (burst suppression within hours of birth in the most severe case); insidious/progressive for ataxia and developmental phenotypes.
• Progression: Generally progressive — worsening motor/developmental trajectory, evolving neuroimaging abnormalities (many patients have normal early imaging that becomes abnormal over time), and in SCAR24, progressive loss of ambulation over decades (one sibling lost independent ambulation at age 39).
• Disease course pattern: Chronic-progressive rather than relapsing-remitting; punctuated by episodes of status epilepticus or status dystonicus that can themselves be acutely life-threatening.
• Disease duration: Chronic, lifelong in survivors; the most severe genotypes are neonatally or infantile lethal (e.g., death at 16 days in one report; the congenital neuropathy phenotype causes "early death in infancy" in a consanguineous family).
• Critical periods: Early infancy appears to be a critical window for both diagnosis (before irreversible neurodevelopmental injury) and, per model-system data, for potential UBA5-upregulation therapeutics (organoid electrophysiology correction was only transient, suggesting narrow/ongoing dosing windows may matter).

9. Inheritance and Population

• Epidemiology: Ultra-rare — approximately 24–25 individuals from ~17–19 families reported in the literature as of the most recent comprehensive reviews (2021 review; 2023 eLife series). True population prevalence/incidence is not established (likely underdiagnosed given phenotypic overlap with other genetic epilepsies/encephalopathies).
• Inheritance pattern: Autosomal recessive.
• Penetrance: Complete for the disease-causing genotype combinations reported, but with a documented threshold effect — biallelic combinations of very mild hypomorphic alleles (e.g., homozygous p.A371T) are reported as asymptomatic in population databases, indicating incomplete penetrance is possible for the mildest allelic combinations depending on residual enzymatic activity.
• Expressivity: Highly variable — spanning fatal neonatal encephalopathy/congenital neuropathy to adult-onset ataxia with normal cognition, driven largely by the combined "allelic strength" of the two inherited variants.
• Genetic anticipation: Not reported/not applicable (not a repeat-expansion disorder).
• Germline mosaicism: Not specifically documented in the literature reviewed.
• Founder effects: p.Ala371Thr shows an elevated carrier frequency consistent with a founder/recurrent allele in Finnish (1/84) and other European (1/200) populations; p.Arg11Trp is a founder variant in a specific consanguineous family lineage.
• Consanguinity: A recognized contributor, particularly for the homozygous severe congenital-neuropathy phenotype (large consanguineous multigenerational family reported).
• Carrier frequency: See p.A371T figures above; overall UBA5 pathogenic-variant carrier frequency in the general population is not separately quantified.
• Population demographics: Reported cases span diverse ancestries; SCAR24 was first reported in Chinese siblings; DEE44 cases span European, Finnish, and other backgrounds. No clear geographic endemicity beyond the Finnish/European founder-allele signal.
• Sex ratio: No sex predilection reported (autosomal recessive).
• Age distribution: Reported individuals span neonates to adults in their late 30s (the oldest reported SCAR24 patient).

10. Diagnostics

Clinical/Laboratory Tests

• No specific disease biomarker exists; diagnosis relies on genetic confirmation in the context of a compatible clinical/EEG/MRI phenotype.
• EEG: Near-universal abnormality — spikes/polyspikes with background slowing and disorganization; hypsarrhythmia in infantile-spasms presentations; burst suppression in the most severe neonatal cases.
• Brain MRI: Delayed myelination, thin/dysmorphic corpus callosum, cerebral/cerebellar atrophy, white matter hyperintensities, diminutive thalami, abnormal hippocampal orientation, and altered U-fiber pattern; often normal in early infancy with abnormalities emerging over time — serial imaging is informative.
• Nerve conduction studies/EMG: Relevant in the neuropathy-predominant phenotype to document severe sensorimotor peripheral neuropathy.

Genetic Testing

• Whole exome sequencing (WES) or whole genome sequencing (WGS) is the primary diagnostic approach given the phenotypic overlap of DEE44 with dozens of other genetic developmental and epileptic encephalopathies; UBA5 is included on epilepsy/DEE gene panels.
• Targeted gene panels for early infantile epileptic encephalopathy / developmental and epileptic encephalopathy routinely include UBA5.
• Single-gene/Sanger confirmation of variants identified by panel/exome sequencing, and segregation testing in parents to confirm compound heterozygosity (trans configuration).
• Functional/biochemical variant classification (as developed in the eLife allelic-series study) is emerging as a research-grade tool to help interpret novel missense VUS by comparison to characterized allelic-strength groups.

Clinical Diagnostic Criteria

No formal consensus diagnostic criteria exist (ultra-rare disease); diagnosis is genotype-driven (biallelic UBA5 pathogenic/likely pathogenic variants) combined with compatible phenotype per OMIM clinical synopsis and case-series-derived phenotype descriptions.

Differential Diagnosis

Other genetic developmental and epileptic encephalopathies (e.g., CDKL5 deficiency disorder, STXBP1-DEE, other early infantile epileptic encephalopathies), other UFMylation-pathway disorders (UFM1, UFC1, UFSP2, UFBP1/DDRGK1, CDK5RAP3 — all now linked to overlapping hypomyelinating leukodystrophy/encephalopathy phenotypes), and other causes of hypotonia/failure-to-thrive with epilepsy.

Screening

No population-based newborn or carrier screening program specifically targets UBA5 given its rarity; carrier screening could theoretically be offered in populations with elevated p.A371T-type founder frequencies, but this is not standard practice.

11. Outcome/Prognosis

• Survival/mortality: Ranges from neonatal/infantile death (most severe genotypes — e.g., death at 16 days from a homozygous severely hypomorphic variant; early infant death in the fatal congenital neuropathy family) to survival into adulthood with milder genotypes (SCAR24 patients surviving into their 30s–40s with progressive but non-lethal disease course).
• Morbidity/function: Severely affected individuals have profound, lifelong intellectual disability, non-ambulation, and dependence on caregivers; refractory epilepsy and dystonia (including life-threatening status dystonicus) are major sources of morbidity.
• Complications: Status epilepticus (a reported cause of death), status dystonicus requiring emergency intervention, failure to thrive/malnutrition, aspiration risk from severe motor impairment.
• Recovery potential: No cure exists; supportive/symptomatic management is the current standard. Investigational UBA5-upregulation approaches (see below) show preclinical proof-of-concept for partial phenotype correction.
• Prognostic factors: Genotype (allelic strength of both variants) is the dominant known prognostic determinant — severe/severe or severe/null combinations are neonatally lethal or profoundly disabling, while mild/mild combinations may be asymptomatic-to-mildly affected (SCAR24-type or subclinical).

12. Treatment

There is no disease-modifying or curative therapy; management is entirely supportive/symptomatic.

Pharmacotherapy

• Antiepileptic drugs (AEDs): Multiple AEDs are typically required given drug-resistant seizures; specific agent selection is individualized and not standardized for this ultra-rare disease. NCIT term: NCIT:C15632/NCIT:C15986 categories apply generically (Pharmacotherapy/anticonvulsant therapy).
• Levodopa: Reported to provide "moderate improvement" in the movement disorder for at least one patient.
• Prophylactic antiepileptic treatment: Used in some patients based on EEG abnormalities even before clinical seizures manifest.

Advanced/Interventional

• Deep brain stimulation (globus pallidus internus, GPi-DBS): Used for medically refractory dystonia/status dystonicus in UBA5-related disorder, with one report describing "dramatic improvement in dystonia" and a dedicated case report of DBS for medically refractory status dystonicus (PMID:37130202, Movement Disorders 2023). NCIT candidate term: device/procedural intervention (DBS has no precise NCIT clinical-action term identified; would require DEVICE modality classification).

Dietary/Supportive

• Ketogenic diet: A generic option for drug-resistant epilepsy broadly (not UBA5-specific evidence identified, but plausible extrapolated management given refractory-epilepsy phenotype); NCIT:C15447 (Dietary Intervention).
• Nutritional support for failure to thrive (feeding tube support commonly needed in severe developmental and epileptic encephalopathies generally).
• Physical, occupational, and speech therapy: Standard supportive rehabilitative care (NCIT:C15302 Physical Therapy; NCIT:C15315 Rehabilitation).

Experimental/Investigational

No registered UBA5-specific clinical trials were identified (ClinicalTrials.gov search did not surface an active interventional trial). Preclinical therapeutic strategies under active research development, targeting the core mechanism (increasing residual UBA5 protein/activity), include: - SINEUP synthetic long non-coding RNA — increased UBA5 translation ~1.5-fold in patient organoids, transiently normalizing aberrant electrophysiology (effect lasted 2–4 days) (Science Translational Medicine, PMID:40333994) - CRISPRa (dCas9-VP64-p65-Rta) gene activation — achieved ~2-fold UBA5 protein increase, restoring ER-homeostasis/UPR markers - Rationale: because the common p.A371T hypomorphic allele is compatible with an asymptomatic state when both alleles are equally mild, modest (not excessive — overexpression is itself detrimental) upregulation of UBA5 expression is hypothesized as a therapeutic strategy for patients carrying at least one A371T-class allele.

Treatment Outcomes

Given the small numbers, no systematic response-rate or adverse-event data exist beyond individual case reports; drug-resistant epilepsy is the norm, and DBS/levodopa responses are anecdotal.

Treatment Strategy

No formal treatment algorithm exists; management follows general refractory-DEE/movement-disorder principles (stepwise AED trials → ketogenic diet consideration → DBS for refractory dystonia) individualized by clinical team, informed by emerging genotype-function data as a potential future guide to prognosis counseling.

13. Prevention

• Primary prevention: Not applicable in the traditional sense (monogenic recessive disease); genetic/carrier counseling for at-risk families (especially those with known founder alleles or consanguinity) is the main preventive lever, alongside prenatal diagnosis or preimplantation genetic testing (PGT) for families with a previously affected child and known biallelic variants.
• Secondary prevention: Early genetic diagnosis via WES/WGS in infants presenting with unexplained early-onset encephalopathy/refractory seizures allows earlier supportive intervention (though no disease-modifying treatment currently changes the trajectory).
• Tertiary prevention: Aggressive seizure and dystonia management (including DBS) to reduce morbidity/mortality from status epilepticus or status dystonicus; nutritional support to prevent complications of failure to thrive.
• Genetic counseling: Recommended for parents of an affected child (25% recurrence risk per pregnancy) and for extended family members in consanguineous or founder-allele-enriched populations (NCIT:C15240 Genetic Counseling).
• Carrier screening: Not part of standard population carrier screening panels currently, but could be considered in populations with elevated p.A371T carrier frequency (e.g., Finnish population) as awareness grows.

14. Other Species / Natural Disease

• No spontaneously occurring UBA5-related disease has been reported in domestic animals, companion animals, or wildlife (OMIA search did not surface a natural veterinary UBA5 disease). This section is not applicable beyond engineered laboratory models (see §15).
• Orthologous gene: UBA5 orthologs are highly conserved; the Drosophila melanogaster ortholog (Uba5) shares 64% amino acid identity / 75% similarity with human UBA5, sufficient for successful "humanization" (replacement with human UBA5 cDNA) in fly disease models.

15. Model Organisms

Mouse

• Germline Uba5 knockout mice are embryonic lethal at E12.5, caused by hematopoietic defects — this precludes direct study of the neurological phenotype and demonstrates that complete loss of UBA5 function is incompatible with development, consistent with the human observation that all reported patients carry at least one partial-function (hypomorphic) allele (MGI:1913913).
• Conditional/hypomorphic mouse alleles that better model human disease were not identified as established in the sources reviewed here — this is a noted gap (relevant to a HUMAN_MODEL_MISMATCH framing: the null mouse model fails to recapitulate the human neurological phenotype and instead demonstrates a distinct hematopoietic-lethal mechanism).

Zebrafish (the leading in vivo model)

• Two independent CRISPR-Cas9-engineered uba5 mutant zebrafish lines: uba5ex1s (exon 1 nonsense/frameshift, p.E5Ffs1, truncated non-functional protein) and uba5ex3d* (exon 3 in-frame deletion of the ATP-binding domain, p.A73_V80del) (Brain Communications 2023, PMC10691876).
• Phenotype recapitulation (RECAPITULATES): 41–45% reduced swimming distance at 6 dpf; 40–50% reduced body length from 14 dpf; severely reduced survival (only 4% surviving past 39 dpf, max lifespan 70 dpf) — closely mirroring human motor impairment, growth failure, and reduced life expectancy.
• CNS findings: cerebellar neuronal degeneration at 14 dpf (abnormal membranous swirls, degenerating mitochondria); no gross brain/cerebellar volume change at 6 dpf.
• PNS findings: peripheral nerve abnormalities at 6 dpf (autophagic structures, large vesicles, elongated/degenerating mitochondria in nerve terminals) — directly modeling the human neuropathy-predominant phenotypic pole.
• Mitochondrial pathology: widespread abnormal cristae, vacuolated/"onion-ring" mitochondria, elevated full-length PINK1 (mitophagy activation), and reduced Ufm1-conjugates to ~30% of wild type — providing the strongest evidence to date for mitochondrial dysfunction as a downstream consequence of UFMylation loss.
• Applications: motor function assays (high-throughput swimming/locomotor tracking), survival/lifespan assays, ultrastructural (EM) study of CNS/PNS/muscle mitochondrial pathology, and validation of variant pathogenicity.

Drosophila melanogaster

• "Humanized" fly models expressing human UBA5 variants under the control of the endogenous Uba5 promoter (replacing/complementing the fly ortholog, 64% identity/75% similarity to human) were used to systematically test 13+ patient missense variants plus synthetic controls (e.g., enzyme-dead p.Cys250Ala) across viability, developmental timing, lifespan, locomotor activity, and bang-sensitivity (seizure-like) assays (eLife 89891).
• Variants stratified into Groups IA/IB/II/III/IV by degree of phenotype rescue, which strongly correlated with in vitro biochemical severity (thermal stability, ATP binding, UbiReal fluorescence-polarization transthiolation assays) — establishing the fly platform as a validated variant-classification tool bridging genotype to phenotype severity, directly informative for VUS interpretation in newly identified patients.
• Clinical correlation: 21/25 analyzed affected individuals carried one Group IA/IB (mild) allele in trans with one Group III/IV (severe) allele, mechanistically explaining why "mild + severe" combinations are viable and symptomatic while "severe + severe" combinations are presumed embryonic/perinatally lethal (paralleling the mouse null-lethality finding).

Patient-Derived Cellular/Organoid Models

• iPSC-derived cortical organoids from two probands (compound heterozygous UBA5 variants) plus isogenic parental controls, and CRISPR-engineered U-87 MG glioma cell lines carrying specific patient genotypes (UBA5^A371T/R55H; UBA5^A371T/F292*) and a benign control (UBA5^A371T/A371T homozygous) (Science Translational Medicine, PMID:40333994; preprint PMID:38328212).
• Fidelity: High construct validity for modeling human-specific neurodevelopmental features (GABAergic interneuron specification, cortical organoid electrophysiology) not accessible in mouse/fish; RECAPITULATES microcephaly (~25% organoid size reduction), GABAergic interneuron deficit (~15% vs ~40% in controls), ER stress/UPR activation, and network-level electrophysiological abnormality.
• Limitations: Organoids model early corticogenesis and lack mature circuit-level, in vivo behavioral correlates (seizures, motor phenotype); therapeutic rescue (SINEUP) was only transient (2–4 days), an unresolved translational gap.
• Research applications: Mechanistic dissection of ER/UPR and GABAergic-lineage pathology; platform for testing UBA5-upregulation therapeutic strategies (SINEUP RNA, CRISPRa) prior to any in vivo/clinical translation.

Summary Table: Key Evidence Citations

Note on gaps: No formal GeneReviews chapter, no MONDO ID, and no large systematic natural-history study (>25 patients) were identified in this search — these represent genuine literature gaps rather than omissions, consistent with UBA5-DEE44's status as an ultra-rare, recently-described (2016) condition. No active registered clinical trial was found. Mouse knockout data reflect a HUMAN_MODEL_MISMATCH-type limitation (embryonic lethality via a hematopoietic, not neurological, mechanism) rather than a validated CNS/PNS disease model, in contrast to the zebrafish and Drosophila platforms.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMC:PMC8208045 (abstract only): "the first gene from the ufmylation pathway... linked to disease"
• closest text in source: "Early infantile epileptic encephalopathy-44 (EIEE44, MIM: 617132) is a previously described condition resulting from biallelic variants in UBA5, a gene involved in a ubiquitin-like post-translational modification system called UFMylation"